Long-term Study of DSP-5423P in Patients With Schizophrenia

PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions

Schizophrenia

Interventions

DRUG

DSP-5423P

40-80mg/day

Trial Locations (1)

38 Sites, Tokyo

All Listed Sponsors

lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT02335658 - Long-term Study of DSP-5423P in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter